Clinical significance of serum levels of soluble interleukin‐2 receptor in patients with localized scleroderma

Summary Localized scleroderma has been reported to be accompanied by abnormal immune reactions, including autoantibody production and lymphocyte activation. Lymphocyte activation can be quantitatively detected by measuring soluble interleukin‐2 receptor (sIL‐2R) in serum samples. In this study, serum sIL‐2R levels were assayed by a sensitive enzyme‐linked immunosorbent assay, in 48 patients with localized scleroderma, in 20 with systemic sclerosis (SSc) and in 20 healthy controls. Serum levels of sIL‐2R were significantly higher in patients with localized scleroderma than in healthy controls. The serum levels of sIL‐2R were correlated with the number of sclerotic lesions, the number of involved areas, the levels of anti‐ssDNA, and the levels of antihistone antibody immunoglobulin M. Moreover, sIL‐2R levels in sera from patients with SSc were also significantly higher than in healthy controls. Elevated serum levels of sIL‐2R in localized scleroderma suggest that lymphocyte activation is one of the early processes in the development of this disease.

[1]  H. Ihn,et al.  Antihistone antibodies in patients with localized scleroderma. , 1993, Arthritis and rheumatism.

[2]  T. Taniguchi,et al.  The IL-2 IL-2 receptor system: A current overview , 1993, Cell.

[3]  K. Takehara,et al.  Anti-single-stranded DNA antibody and muscle involvement in localized scleroderma. , 1990, Archives of dermatology.

[4]  P. Limburg,et al.  Changes in plasma levels of interleukin‐2 receptor in relation to disease exacerbations and levels of anti‐dsDNA and complement in systemic lupus erythematosus , 1990, Clinical and experimental immunology.

[5]  E. Keystone,et al.  Serial levels of soluble interleukin 2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlations with disease activity. , 1990, The Journal of rheumatology.

[6]  J. Seibold,et al.  Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations. , 1990, Arthritis and rheumatism.

[7]  J. Symons,et al.  Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? , 1988, Journal of autoimmunity.

[8]  R. Wolf,et al.  Soluble interleukin-2 receptors in systemic lupus erythematosus. , 1988, Arthritis and rheumatism.

[9]  T. Medsger,et al.  Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. , 1986, Annals of internal medicine.

[10]  D. Nelson,et al.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.

[11]  J. Rasmussen,et al.  Juvenile linear scleroderma associated with serologic abnormalities. , 1985, Archives of dermatology.

[12]  Y. Moroi,et al.  Antinuclear antibodies in the relatives of patients with systemic sclerosis , 1985, The British journal of dermatology.

[13]  T. Waldmann,et al.  Characterization of the human receptor for T-cell growth factor. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Y. Moroi,et al.  Antinuclear antibodies in localized scleroderma. , 1983, Arthritis and rheumatism.

[15]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[16]  G. Rodnan.  Growth and Development of Rheumatology in the United States—A Bicentennial Report , 1977 .

[17]  Scarola Ja,et al.  Proceedings: Serologic abnormalities and their significance in localized scleroderma. , 1975 .

[18]  Interleukin 2 , 1993, Seminars in oncology.

[19]  Rodnan Gp.  When is scleroderma not scleroderma? The differential diagnosis of progressive systemic sclerosis. , 1981 .

[20]  L. Shulman,et al.  Proceedings: Serologic abnormalities and their significance in localized scleroderma. , 1975, Arthritis and rheumatism.

[21]  H. Christianson,et al.  Localized scleroderma; a clinical study of two hundred thirty-five cases. , 1956, A.M.A. archives of dermatology.